Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Leigh Van Devender

Nurse Practitioner, Gerontology Oxford, MS Nurse Practitioner

NPI 1376198192 CMS profile 10496901

504 Azalea Dr Ste A, Oxford, MS 38655

Open in the dashboard

General payments

$16,270

884 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leigh Van Devender of Oxford, MS is reported in the CMS Open Payments database as having received $16,270 across 884 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,230 175
2024 General $3,958 198
2023 General $3,282 179
2022 General $2,659 139
2021 General $3,141 193

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leigh Van Devender
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Leigh Van Devender were reported at $3,230. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Leigh Van Devender Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $3,141 $133 $44–$396 $132
2022 $2,659 $142 $48–$452 $149
2023 $3,282 $158 $53–$482 $160
2024 $3,958 $171 $55–$533 $164
2025 $3,230 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $4,079 217 payments
  2. AbbVie, Inc. $3,602 182 payments
  3. Janssen Biotech, Inc. $1,343 63 payments
  4. Novartis Pharmaceuticals Corporation $1,221 106 payments
  5. UCB, Inc. $1,104 72 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $966 50 payments
  7. Pfizer Inc. $645 38 payments
  8. AstraZeneca Pharmaceuticals LP $638 34 payments
  9. Lilly USA, LLC $427 21 payments
  10. Aurinia Pharma U.S., Inc. $376 19 payments
  11. Other $1,868 82 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $15,983 880 payments
  2. Education $287 4 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $2,715 137 payments
  2. Otezla $2,153 119 payments
  3. Enbrel Inflammation $1,174 73 payments
  4. TREMFYA $989 40 payments
  5. Enbrel Inflammation $985 66 payments
  6. COSENTYX $928 84 payments
  7. Cimzia $760 53 payments
  8. XELJANZ $645 38 payments
  9. SKYRIZI $586 27 payments
  10. EVENITY $560 30 payments
  11. Other $8,105 429 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

2,466

Median for Nurse Practitioner: 389

Drug cost

$2,694,040

Median for Nurse Practitioner: $21,885

Branded share of claims

30.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 108 $821,166
Rinvoq Upadacitinib Brand 92 $562,236
Enbrel Sureclick Etanercept Brand 57 $399,982
Taltz Autoinjector (2 Pack) Ixekizumab Brand 16 $211,675
Actemra Actpen Tocilizumab Brand 56 $194,108
Cimzia (2 Pack) Certolizumab Pegol Brand 19 $123,196
Enbrel Mini Etanercept Brand 13 $92,368
Kevzara Sarilumab Brand 19 $77,915
Orencia Clickject Abatacept Brand 13 $71,849
Benlysta Belimumab Brand 20 $67,186

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$40,565

Medicare's payments for the services billed

Medicare patients

491

Average age 71

Services billed

1,078

360 women, 131 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 45%
Diabetes 31%
Ischemic heart disease 29%
Chronic kidney disease 25%
Depression 23%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
$448 92 —
COSENTYX
$358 — —
Enbrel
$302 70 —
Otezla
$302 — —
SKYRIZI
$265 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

884 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Gerontology in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record